| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | MRK Merck & Co., Inc. | Romanelli Joseph57 | President, Human Health Int?l | Sell | 1,000 | $124.89 | $124,887.90 | -4.9% | +3.7% | -29.8% | |
| Feb 13, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith49 | Sr. VP, General Counsel &Sec. | Sell | 250 | $56.04 | $14,010.00 | -0.7% | +22.4% | +8.5% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,352 | $132.89 | $179,673.63 | -1.0% | +1.7% | -12.4% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 716 | $133.03 | $95,252.77 | -8.7% | +1.7% | -12.4% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 796 | $133.04 | $105,902.15 | -4.2% | +1.7% | -12.4% | |
| Feb 13, 2024 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 341 | $55.31 | $18,860.71 | -0.6% | +41.9% | +49.6% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,114 | $132.96 | $148,121.78 | -4.5% | +1.7% | -12.4% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 1,098 | $133.01 | $146,050.36 | -2.6% | +1.7% | -12.4% | |
| Feb 13, 2024 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,098 | $132.99 | $146,028.40 | -2.7% | +1.7% | -12.4% | |
| Feb 13, 2024 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 3,211 | $188.09 | $603,956.90 | -7.8% | -8.5% | -5.2% | |
| Feb 12, 2024 | IRWD Ironwood Pharmaceuticals Inc | Shetzline Michael67 | CMO,SVP,Head-res&Drug | Sell | 38,618 | $15.24 | $588,538.32 | -10.2% | -56.5% | -87.8% | |
| Feb 12, 2024 | IRWD Ironwood Pharmaceuticals Inc | Davis Andrew73 | SVP, Chief Business Officer | Sell | 9,846 | $15.24 | $150,053.04 | -4.5% | -56.5% | -87.8% | |
| Feb 12, 2024 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 177,164 | $15.24 | $2,699,979.36 | -17.5% | -56.5% | -87.8% | |
| Feb 12, 2024 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 7,908 | $15.24 | $120,517.92 | -5.6% | -56.5% | -87.8% | |
| Feb 12, 2024 | IRWD Ironwood Pharmaceuticals Inc | John Minardo69 | Chief Legal Officer | Sell | 47,380 | $15.24 | $722,071.20 | -17.4% | -56.5% | -87.8% | |
| Feb 12, 2024 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 39,872 | $10.03 | $399,984.31 | -11.1% | +29.5% | +338.0% | |
| Feb 12, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 26,919 | $10.03 | $270,046.18 | -8.0% | +29.5% | +338.0% | |
| Feb 9, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 206,257 | $740.60 | $152,753,427.71 | - | +4.2% | +18.7% | |
| Feb 9, 2024 | MRK Merck & Co., Inc. | Li Dean Y73 | Executive VP &President, Mrl | Sell | 14,702 | $125.50 | $1,845,083.36 | -24.1% | +4.5% | -28.5% | |
| Feb 9, 2024 | JNJ Johnson & Johnson | Taubert Jennifer L60 | EVP, Ww Chair, Pharmaceuticals | Sell | 59,397 | $156.27 | $9,281,969.19 | -29.6% | -4.4% | -2.3% | |
| Feb 8, 2024 | SBFM Sunshine Biopharma Inc. | Slilaty Steve N. | Chief Executive Officer | Buy | 20,000 | $0.10 | $2,000.00 | +200.0% | -95.7% | -99.5% | |
| Feb 8, 2024 | PBH Prestige Consumer Healthcare Inc. | Fritz Mary Beth57 | SVP Quality &Regulatory | Sell | 5,336 | $69.00 | $368,184.00 | -25.1% | +1.5% | +26.5% | |
| Feb 8, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 8,743 | $740.06 | $6,470,335.84 | - | +5.3% | +19.4% | |
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 2,580 | $139.16 | $359,041.22 | -1.0% | +3.4% | -8.8% | |
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 5,314 | $138.74 | $737,270.71 | -0.5% | +3.4% | -8.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.